News

Equifax's Upcoming Investor Conferences and Participation Details

Equifax's Upcoming Investor Conferences and Participation Details

Equifax's Participation in November Investor Conferences

Equifax® (NYSE: EFX) is gearing up for several significant investor conferences this November. Mark W. Begor, the Chief Executive Officer, is scheduled to participate in the prestigious J.P. Morgan 2024 Ultimate Services Conference, where he will engage in a Fireside Chat to share insights about the company.

Key Conference Dates and Attendance

On Thursday, November 14, 2024, Mr. Begor will take part in the conference, specifically highlighting Equifax's innovative approaches and ongoing initiatives. Additionally, John Gamble, the Chief Financial Officer, along with Trevor Burns, Senior Vice President of Corporate Investor Relations, will represent the company at the RBC 2024 Global Technology, Internet, Media & Communications Conference on Tuesday, November 19, 2024.

During the RBC conference, Mr. Gamble and Mr. Burns will also hold a Fireside Chat, providing further opportunities to discuss Equifax's strategic direction and the technology that supports its activities. This session is set for 4:40 p.m. Eastern Time, offering an excellent platform for investors to connect with the company's leadership.

Access to Livestream and Replays

Equifax invites all interested investors to join the livestream of the Fireside Chat events. Investors can tune in to hear first-hand insights and updates directly from the executive team. For those unable to attend live, replays will be made available within 24 hours after the conclusion of each event on Equifax’s Investor Relations website.

Participation in Additional FinTech Conferences

Mr. Trevor Burns is also slated to attend the FT Partners FinTech Conference on November 20, 2024. This event emphasizes the importance of innovation within the financial technology landscape, and Equifax’s participation underscores its commitment to being at the forefront of industry developments.

About Equifax

Equifax is a global data, analytics, and technology company that plays a vital role in assisting various sectors, including financial services and government entities, in making informed decisions. With a strong focus on enhancing the confidence of their clients, Equifax utilizes a unique blend of data, analytics, and cloud technology.

With its headquarters located in Atlanta and nearly 15,000 dedicated employees, Equifax operates across 24 countries encompassing North America, Central and South America, Europe, and the Asia Pacific region. The company is committed to driving progress through knowledge, thus empowering financial institutions and businesses with actionable insights.

Frequently Asked Questions

1. What is the purpose of Equifax participating in investor conferences?

Equifax participates in investor conferences to engage with investors, share insights about their strategies, and enhance transparency about their operations and initiatives.

2. How can investors access the livestream of the Fireside Chats?

Investors can access the livestream of the Fireside Chats by visiting Equifax’s Investor Relations website on the scheduled dates of the conferences.

3. Who are the key executives participating in the November conferences?

Mark W. Begor, John Gamble, and Trevor Burns are the key executives from Equifax participating in the conferences during November.

4. Will there be replays available for those who miss the livestream?

Yes, replays of the Fireside Chats will be available on Equifax’s Investor Relations website within 24 hours after the events.

5. What role does Equifax play in the global economy?

Equifax provides crucial data, analytics, and insights that help financial institutions and businesses make informed decisions, thereby playing a significant role in the global economy.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 41

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 36

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 32

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 36

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading
Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 37

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 26

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading

Top 5 Most Recently Viewed Articles

Growth of Middle-Class Investors through Mutual Fund Ownership

Updated Category News Views 149

Mutual Funds and the Rise of the Middle-Class Investor Over recent years, mutual fund ownership has surged among middle-class families. According to insights from the Investment Company Institute (ICI), this trend signifies a vital transition as middle-income households increasingly seek investment opportunities. The growing presence of mutual funds in the American...

Continue Reading
Rques Exchange Reinforces Its Brand with Compliance Strategy

Updated Category News Views 180

Rques Exchange Reinforces Brand with Regulatory Frameworks Rques Exchange is taking significant steps to enhance its brand by emphasizing its commitment to regulatory alignment, operational transparency, and governance integrity in various markets. With global authorities increasingly scrutinizing digital asset platforms, Rques aims to position itself as a technology...

Continue Reading
Business Growth and Confidence: Provident Bank's Insights

Updated Category News Views 120

Increasing Business Confidence for the Future Recently, Provident Bank, a prominent financial institution based in New Jersey, conducted an enlightening Economic Outlook survey. This survey reflects the sentiments of 1,000 business leaders regarding the 2025 economic prospects. The results showcase a robust sense of optimism and confidence among businesses as they look...

Continue Reading
Performance Food Group Co: A Five-Year Stock Journey

Updated Category News Views 219

Unlocking the Value of Investment in Performance Food Group Co Performance Food Group Co (NYSE: PFGC) has delivered impressive returns over the last five years, standing out in the competitive market landscape. With an annualized return that has surpassed the market by 9.42%, investors have seen an average growth rate of around 24.5%. This stock is not just another entry...

Continue Reading
Understanding Rathbones Group Plc's Disclosure Requirements

Updated Category News Views 227

Key Information on Disclosure Requirements Understanding how companies disclose their shareholding is crucial for investors and stakeholders alike. Rathbones Group Plc plays an essential role in managing these disclosures, particularly regarding relevant securities that represent substantial interests in listed companies. Full Name of the Discloser The full name of the...

Continue Reading